Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls

Intern Emerg Med. 2023 Oct;18(7):1879-1886. doi: 10.1007/s11739-023-03335-3. Epub 2023 Jun 20.

Abstract

Cardiac amyloidosis (CA) is an uncommon, progressive, and fatal disease; the two main forms that can affect the heart are transthyretin CA and light chain CA (AL-CA). AL-CA is a medical urgency for which a diagnostic delay can be catastrophic for patients' outcome. In this manuscript, we focus on the pearls and pitfalls that are relevant to achieve a correct diagnosis and to avoid diagnostic and therapeutical delays. Through the aid of three unfortunate clinical cases, some fundamental diagnostic aspects are addressed, including the following: first, a negative bone scintigraphy does not exclude CA, with patients with AL-CA frequently showing no or mild cardiac uptake, and its execution should not delay hematological tests; second, fat pad biopsy does not have a 100% sensitivity for AL amyloidosis and, if negative, further investigations should be performed, particularly if the pre-test probability is high. Third, Congo Red staining is not sufficient to reach a definitive diagnosis and amyloid fibrils typing with mass spectrometry, immunohistochemistry, or immunoelectron microscopy is crucial. To achieve a timely and correct diagnosis, all the necessary investigations must be performed, always considering the yield and diagnostic accuracy of each examination.

Keywords: AL amyloidosis; Cardiac amyloidosis; Diagnostic pitfalls.

Publication types

  • Review

MeSH terms

  • Amyloidosis* / diagnosis
  • Biopsy
  • Cardiomyopathies* / diagnosis
  • Congo Red
  • Delayed Diagnosis
  • Humans
  • Immunoglobulin Light-chain Amyloidosis* / diagnosis

Substances

  • Congo Red